
News|Articles|December 3, 2025
Accelerate Cell Line Development with GPEx® Lightning: Speed, Stability, and Industry-Leading Titers
Author(s)Catalent
Catalent’s GPEx® Lightning platform delivers stable, high-yield cell lines with unmatched speed—achieving titers up to 15g/L for mAbs and 11g/L for bispecifics. With 25-day pool generation and up to 12 weeks saved on development timelines, this offering sheet outlines key performance metrics and benefits that make GPEx® Lightning a game-changer for biologics developers.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Genentech Expands RNAi Pipeline Through Global Licensing Deal
2
AdvanCell Targets GI Cancer With Peptide-Driven Lead-212 Radiotherapy
3
Pfizer Phase IIb Data Support Monthly GLP-1 Dosing for Obesity
4
Industry Outlook 2026: How AI and Payer Pressure Impact Biopharma R&D (Part 1)
5